IndraLab

Statements

USP5 inhibits calcium(2+). 5 / 5
| 5
reach
"The overexpression of Ca v 3.2 accompanied by the upregulation of Egr-1 and USP5 in the DRG following CPA at 400 mg/kg (see Fig. 4 ) or CPA at 200 mg/kg in combination with TPEN (see Fig. 6 ), suggest[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
29129814
reach
"On the other hand, protein levels of USP5, which inhibits proteasomal degradation of Ca v 3.2 ( Garcia-Caballero et al., 2014 ), started to increase on day 3 after the onset of bortezomib treatment, a[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
30552955
reach
"Protein levels of USP5, known to inhibit proteasomal degradation of Ca v 3.2 ( Garcia-Caballero et al., 2014 ), did not change on day 6, but increased on day 14 after L5SNC ( Fig. 2 B)."
32971090
reach
"The bortezomib compound increased the protein levels of Ca 3.2 in DRG and induced peripheral neuropathy through the upregulation of USP5 that inhibits proteasomal degradation of Ca 3.2 in mice (Tomita et al., 2020)."
37529702
reach
"As illustrated in Fig. 3 A and B , Isot attenuated both Ca 2+ entry and Ca 2+ entry in response to AA in a concentration-dependent manner, although higher concentrations were required to prevent 30 μM[MISSING/INVALID CREDENTIALS: limited to 200 char for Elsevier]"
15789621